Erik Darius Mardiwidyo and Bedjo Stefanus as Sellers Together with Yenfrino Gunadi and Lee Yan Gwan Representing Buyers
Jakarta, August 25, 2021 – In line with plans to expand and increase product diversification, as well as production capacity, PT. Pyridam Farma Tbk with the issuer name PYFA signed an agreement to acquire 100% shares of PT. Holi Pharma.
Director of PT. Pyridam Farma Tbk (PYFA), Yenfrino Gunadi said “This expansion will increase the group’s overall production capacity by more than three times the existing capacity. We believe that this acquisition will strengthen our position in the Indonesian pharmaceutical industry.” Yenfrino further added that this acquisition process is the first step of various initiatives being developed.
In the future, PT Pyridam Farma. Tbk (PYFA) will continue to innovate by establishing strategic partnerships with various industries to advance the healthcare industry in Indonesia and present products that meet the needs of the Indonesian people.
About PT Pyridam Farma Tbk.
PT Pyridam Farma Tbk is a pharmaceutical company with main business in the form of production and/or distribution of modern and traditional medicines as well as distribution of medical devices such as laboratory equipment and PCR test kits. The company was founded in 1976 and has been a public company and has been listed on the Indonesia Stock Exchange since 2001.
PT Pyridam Farma Tbk. manufactures a wide range of pharmaceutical products such as Antibiotics, Vitamins, Supplements, and Traditional Herbal Treatments. The company has more than 200 products in the form of tablets, caplets, capsules, cream syrups, and ointments. In addition, PT Pyridam Farma Tbk. also manufactures prescription products such as penicillin and non-penicillin antibiotics, and painkillers, as well as non-prescription products for vitamins, cold and cough suppressants, and antipyretics.
